Compare Amgen, Inc. (AMGN) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ON Holding AG — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while ON Holding AG trades at $38.45 (market cap $12.85B). The key difference: Amgen, Inc. is far larger — about 15.3× ON Holding AG's market cap, and Amgen, Inc. pays a 2.77% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| AMGN | ONON | |
|---|---|---|
Market Cap | $196.12B | $12.85B |
Sector | Health | Technology |
52-Week High | $388.16 | $54.24 |
52-Week Low | $271.18 | $31.88 |
Enterprise Value | $241.41B | $12.17B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ONON trades at $38.54, up 4.81% today, with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from robust fundamentals including 63.88% gross margins and 15.5% ROE. Analyst sentiment is overwhelmingly positive with a $47.33 consensus target, though technical indicators suggest near-term resistance at $39.
Outlook remains favorable given consistent earnings outperformance and margin expansion, but elevated valuation multiples and bearish technical trends present near-term risks. The primary opportunity lies in continued execution against growth targets, while risks include market volatility and competitive pressures in the athletic apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
